Effect of Iron Deficiency Anemia and Other Clinical Conditions on Hemoglobin A1c Levels by Domagoj Vučić et al.
SEEMEDJ 2019, VOL 3, NO. 2 Hemoglobin A1c Levels Influences 
76 Southeastern European Medical Journal, 2019; 3(2) 
 
Review article 
Effect of Iron Deficiency Anemia and Other Clinical Conditions on 
Hemoglobin A1c Levels 1 
Domagoj Vučić 1,  Karolina Veselski 1, Zvonimir Bosnić ² 
1 General hospital Dr Josip Benčević, Slavonski Brod, Croatia 
2 Health Center Slavonski Brod, Croatia  
 
 




                                                     
Received: Sep 1, 2019; revised version accepted: Dec 5, 2019; published: Dec 16, 2019 
  




Iron deficiency anemia is the most common type of anemia in the world, the most common form of 
malnutrition deficit with a prevalence of 50% affecting the developed countries as well as 
developing countries with a strong influence on social and economic development. According to 
current guidelines of the American Diabetes Association (2019.) glycated hemoglobin (HbA1c) is a 
reflection of the patient's glycemic status in the last three months and is used for monitoring of 
therapeutic effect as well as for diagnostic purposes. Previous studies have proven that not only iron 
deficiency anemia but also a range of other clinical conditions can affect the level of HbA1c 
independent of glycemic status. The exact mechanism of the effect of iron deficiency on glycated 
hemoglobin levels remains unknown and is still at the hypothesis level. Studies have proven that 
treatment of iron deficiency anemia leads to better control of HbA1c level, regardless of whether 
the patient is diabetic or not. A small number of studies have noted a correlation between iron 
deficiency and levels of glycated hemoglobin, thus further research on larger number of patients is 
certainly necessary in order to improve the therapeutic possibilities for patients with diabetes, more 
accurately diagnose and understand the pathophysiology of formation and influence on glycated 
hemoglobin levels. 
 
(Vučić D, Veselski K, Bosnić Z. Effect Of Iron Deficiency Anemia And Other Clinical Conditions On 
Hemoglobin A1c Levels. SEEMEDJ 2019; 3(2); 76-81) 
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Introduction 
Iron deficiency anemia in today's modern world 
is the most common form of malnutrition and the 
most common form of anemia. Globally, iron 
deficiency is the cause of 50% of all anemias (1). 
Hemoglobin A1c (HbA1c) is a glycated 
hemoglobin, which is used to monitor average 
value of glycemic index of the patient in the last 
3 months (2). HbA1c is produced by glycation of 
the terminal amino acid valine at the β chain of 
hemoglobin and, unlike other markers for 
monitoring glycemic status, is less susceptible 
to daily fluctuations depending on diet, physical 
activity or disease (3). According to the latest 
guidelines of the American Diabetes Association 
(2019), the level of HbA1c ≥ 6.5% is the criteria for 
the diagnosis of diabetes (3). Various other 
factors can also affect glycated hemoglobin 
levels such as hemolytic anemia (4), 
hemoglobinopathies (5), acute blood loss (6), 
pregnancy (7) and uremia in chronic renal failure 
(8). What can be concluded is that the level of 
hemoglobin A1c is not only related to diabetes 
and glycemic index, but that different factors 
can affect the level of the same (Table 1).   
Table 1. Diseases and clinical conditions 
affecting hemoglobin A1c level 
HbA1c≥6.5% 
Diabetes Mellitus 
Chronic renal failure 
Uremia 
Iron deficiency anemia 
Hemoglobinopathies 
Hemolytic anemia 
Acute blood loss 
Pregnancy 
Note: Summarized findings from studies to date on the most 
common diseases and clinical conditions that affect the value of 
HbA1c levels. 
Therefore, it is of the utmost importance to 
identify comorbidities that may affect the level 
of glycated hemoglobin before its level is taken 
into account for diagnostic and therapeutic 
purposes. New studies have provided data on 
alternative glycemic markers that are not as 
susceptible to these comorbidities and that can 
be used to monitor glycemic status in particular 
patient populations, but their application has not 
yet become widely used. 
 
From past to present 
Previous studies which examined the correlation 
of sideropenic anemia and HbA1c levels 
(depending or independent of the patient's 
glycemic status) have shown conflicting results. 
Books and colleagues examined HbA1c values 
in 35 patients with iron dificiency anemia without 
proven diabetes, and found significantly 
elevated levels of HbA1c in patients with iron 
deficiency anemia and normalization of values 
after iron substitution therapy (9). Similar results 
were obtained in the studies of Sluiter et al. (10) 
and Mitchell et al. (11) who attempted to explain 
the correlation of HbA1c and sideropenic anemia 
by alternation of hemoglobin structure and 
HbA1c levels in old and newly synthesized 
erythrocytes. According to the conclusion of 
Sluiter et al., hemoglobin glycation is an 
irreversible process that is present in 
accordance with the erythrocyte lifetime. 
A prospective study from 2010, on a small 
sample of patients with proven diabetes mellitus 
and chronic renal failure (stage IIIB-IV), 
examined the effect of intravenous iron 
supplementation and erythropoietin stimulating 
agents (ESA) on HbA1c values. Both therapeutic 
choices led to a statistically significant decrease 
in HbA1c (12). Similar results were obtained in 
patients with diabetes without developed renal 
insufficiency (13-16). 
CLEVER was the first study to test the 
hypothesis that intravenous administration of 
iron carboximaltosis leads to a reduction in 
HbA1c levels in patients with type 2 diabetes and 
sideropenic anemia, thereby improving 
metabolic status and quality of life. Organized as 
a randomized, single-blind study, it was 
conducted on subjects divided into two groups; 
study group (treated with iron carboximaltosis) 
and control group (treated with placebo). The 
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findings show that iron deficiency is associated 
with an increased risk of developing insulin 
resistance and obesity, and iron excess with the 
development of diabetes (the effect of 
pancreatic beta-cell stimulation on enhanced 
insulin secretion) (17).  
A 2016. cross-sectional study conducten on 150 
patients (75 patients with iron deficiency anemia 
and 75 patients without anemia) examined 
HbA1c values relative to the degree of 
sideropenic anemia. Anemia severity was 
defined as mild anemia (Hb 120-129 g/L for men 
and 110-119 g/L for women), moderate anemia 
(Hb 90-119 g/L for men and 80-109 g/L for 
women) and severe anemia (Hb <90 g/L for men 
and <80 g/L for women). An elevated HbA1c 
was found in the patient with anemia in 
proportion to the degree of iron deficiency. 
Upon completion of the study, an increased 
HbA1c value was observed in a group of patients 
with iron deficiency anemia that correlated with 
the severity of the anemia (18). Similar results 
have been reported in other studies (19-20).  
Increased glucose during pregnancy is now a 
well-known risk factor for the development of 
perinatal complications of mother and child, so 
strict control of the glycemic index during 
pregnancy is of particular importance. Pregnant 
women with known gestational diabetes have a 
significantly higher risk of developing type 2 
diabetes at the end of pregnancy than pregnant 
women with normal glucose levels during 
pregnancy (21). Studies have shown that 
hemoglobin A1c during pregnancy (the gold 
standard of glycemic control) is not a true 
reflection of the glycemic status due to frequent 
iron deficiency anemia (22-23). Studies also 
noted that glycated albumin (GA) values were 
well maintained throughout pregnancy, 
suggesting that elevated glycated hemoglobin 
during gestation could be independent of 
glycemic index and that glycated serum 
albumin presents more accurate factor for 
glycemic control in pregnancy. 
Furthermore, some studies found no correlation 
between Hba1c values in patients with iron 
deficiency anemia and control group (24-25), 
other studies have reported lower values of 
HbA1c in diabetic patients with sideropenic 
anemia compared to diabetics without anemia 
(26), while other studies found elevated HbA1c 
values upon completion of substitution therapy 
in patients with iron deficiency anemia (unknown 
variables)  (27).  
 
Disclosure 
In conclusion, HbA1c is widely used today as a 
diagnostic tool for diabetes and a means of 
controlling the patient's glycemic status. 
Different clinical conditions and diseases may 
affect the erythropoiesis process with an impact 
on HbA1c levels. Numerous clinical studies, 
mostly based on a small number of patients, 
have confirmed that in the presence of iron 
deficiency anemia, HbA1c levels are elevated 
even in non-diabetic patients with normal 
glycemic status (Table 2).  
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Table 2. Results of studies examining the association between hemoglobin A1c and sideropenic 
anemia 
Author and 






















HbA1c % (control 
group) 
Shanti et al. 
2013. 
50 yes no no data / 
3.68 
106±1.4 7.6±0.5 5.5±0.8 
Alap L. 
Christy et al. 
2014. * 
120 yes yes no data / 
11.41 





50 yes no 2.7 / 7.51 61.8 6.60±0..1 5.48±0.56 
Rajagopal et 
al. 2016. 
75 yes no 2.12 / 
120.9 
114.6 6.84±0.07 5.12±0.04 
Sinha et al. 
2011. 
50 yes no no data / 
7.0 
62 4.6±0.6 5.5±0.6 
Solomon et 
al. 2019. * 
174 yes yes no data / 
no data 
99.7 6.18±1.57 7.74±1.81 
* control group; diabetic patients without iron deficiency anemia  
All numeric data expressed as mean values 
 
The expected elevated values of glycated 
hemoglobin in patients with diabetes are well 
correlated with diabetes control, therefore, in 
patients with controlled blood glucose levels, 
HbA1c is expected to be less than 6.5% (3). The 
initial belief that the level of glycated 
hemoglobin is proportional exclusively to 
glycemic status, has been rejected. The 
mechanism by which iron deficiency anemia 
affects the level of HbA1c remains unknown, 
largely based on hypotheses. From the 
foregoing, it is suggested that the iron status of 
the patient be taken into account before 
interpetation of the HbA1c value, with or without 
proven diabetes. Early diagnosis and treatment 
of iron deficiency anemia in patients with 
diabetes may improve glycemic control and 
delay the onset of complications (28). As there is 
not enough studies on a large sample from this 
still-unexplained pathophysiological 
mechanism, further research is needed in the 
future to elucidate the correlation of hemoglobin 
glycation and iron deficiency. 
Precisely because the limitations of hemoglobin 
A1c are known today, there is great interest in 
the use of alternative glycemic markers. Among 
the alternative markers that can be used as a 
complement to hemoglobin A1c is glycated 
albumin. As the level of glycated hemoglobin is 
dependent on red blood cell turnover, albumins 
have a shorter half-life, therefore indicating a 
glycemic index of the last 2-3 weeks. 
Postprandial glucose values are also better in 
states with marked disease progression, such as 
in type 1 fulminant diabetes mellitus. Restrictions 
on the use of GA are pathological conditions 
related to blood albumin levels such as 
nephrotic syndrome, liver disease, obesity, 
glucocorticoid administration, Cushing's 
syndrome and hyperthyroidism. Regardless of 
the known, routine administration of glycated 
hemoglobin has not yet taken root in clinical 
practice, which will require long-term 
prospective studies (29-31). 
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